Literature DB >> 12084797

Age-associated cardiomyopathy in heterozygous carrier mice of a pathological mutation of carnitine transporter gene, OCTN2.

E Xiaofei1, Yasuhiko Wada, Miwako Dakeishi, Fujiko Hirasawa, Katsuyuki Murata, Hirotake Masuda, Toshihiro Sugiyama, Hiroko Nikaido, Akio Koizumi.   

Abstract

The purpose of this study was to test whether heterozygotes of juvenile visceral steatosis mice, a model for systemic carnitine deficiency, may develop age-associated cardiomyopathy. Tissue morphological observations were carried out by light and electron microscopy to compare the heterozygous and age-matched control mice at periods of 1 and 2 years. Possible effects of the pathological mutation on lipid and glucose levels was also evaluated in humans and mice. Except mild increases in serum cholesterol levels in male heterozygous mice and humans, no changes were found in other factors, indicating that none of the confounding factors seems to be profound. Results demonstrated that heterozygous mice had larger left ventriclular myocyte diameters than the control mice. Morphological changes in cardiac muscles by electron microscopy revealed age-associated changes of lipid deposition and abnormal mitochondria in heterozygous mice. Two out of 60 heterozygous cohort and one out of nine heterozygous trim-kill mice had cardiac hypertrophy at ages older than 2 years. The present study and our previous work suggest that the carrier state of OCTN2 pathological mutations might be a risk factor for age-associated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084797     DOI: 10.1093/gerona/57.7.b270

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  6 in total

1.  Cardiomyopathy and carnitine deficiency.

Authors:  Cristina Amat di San Filippo; Matthew R G Taylor; Luisa Mestroni; Lorenzo D Botto; Nicola Longo
Journal:  Mol Genet Metab       Date:  2008-03-11       Impact factor: 4.797

Review 2.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

Review 3.  Primary carnitine deficiency and cardiomyopathy.

Authors:  Lijun Fu; Meirong Huang; Shubao Chen
Journal:  Korean Circ J       Date:  2013-12       Impact factor: 3.243

4.  Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency.

Authors:  Jan Rasmussen; Allan M Lund; Lotte Risom; Flemming Wibrand; Hannes Gislason; Olav W Nielsen; Lars Køber; Morten Duno
Journal:  Mol Genet Metab Rep       Date:  2014-05-22

Review 5.  Carnitine Inborn Errors of Metabolism.

Authors:  Mohammed Almannai; Majid Alfadhel; Ayman W El-Hattab
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

Review 6.  The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis.

Authors:  Mario Bonomini; Victor Zammit; José C Divino-Filho; Simon J Davies; Lorenzo Di Liberato; Arduino Arduini; Mark Lambie
Journal:  J Nephrol       Date:  2020-08-07       Impact factor: 3.902

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.